2025
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins
Strigari L, Schwarz J, Bradshaw T, Brosch-Lenz J, Currie G, El-Fakhri G, Jha A, Mežinska S, Pandit-Taskar N, Roncali E, Shi K, Uribe C, Yusufaly T, Zaidi H, Rahmim A, Saboury B. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins. Journal Of Nuclear Medicine 2025, jnumed.124.268186. PMID: 39848769, DOI: 10.2967/jnumed.124.268186.Peer-Reviewed Original ResearchRadiopharmaceutical therapyNuclear oncologySociety of Nuclear MedicinePredictive dosimetryDosimetric informationTreatment planningTreatment outcomesLack of reimbursementTreatment personalizationDose responseTreatment optimizationEtiological mechanismsRobust security measuresPatient consentReal-world systemsNuclear medicineCross-border data sharingPatientsTreatmentEthical approval
2024
Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics
Hong J, Bae S, Cavinato L, Seifert R, Ryhiner M, Rominger A, Erlandsson K, Wilks M, Normandin M, El-Fakhri G, Choi H, Shi K. Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics. Theranostics 2024, 14: 7122-7139. PMID: 39629134, PMCID: PMC11610134, DOI: 10.7150/thno.99516.Peer-Reviewed Original Research
2023
Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer
Pasquini L, Morris M. Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. 2023, 387-405. DOI: 10.1007/978-3-031-39005-0_19.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerRadium-223Radiopharmaceutical therapyTreatment of metastatic castration-resistant prostate cancerMinimal bone marrow toxicityRadium-223 dichlorideVisceral metastatic diseaseBone marrow toxicityNearby cancer cellsBone painMarrow toxicityMetastatic diseaseOverall survivalCombination therapyMetastatic spreadBone involvementAlpha therapyClinical developmentTreatment strategiesPalliative effectCancer cellsCancerBone
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply